These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19094217)

  • 1. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.
    Lederman MM; Jump R; Pilch-Cooper HA; Root M; Sieg SF
    Retrovirology; 2008 Dec; 5():116. PubMed ID: 19094217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future microbicide approaches aimed at preventing HIV infection in women.
    Pozzetto B; Delézay O; Brunon-Gagneux A; Hamzeh-Cognasse H; Lucht F; Bourlet T
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):167-83. PubMed ID: 22339191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay.
    Watson KM; Buckheit CE; Buckheit RW
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2787-96. PubMed ID: 18559653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbicides: a new hope for HIV prevention.
    ; Gupta SK
    Indian J Med Res; 2011 Dec; 134(6):939-49. PubMed ID: 22310826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HIV attachment and entry for therapy.
    Strizki J
    Adv Pharmacol; 2008; 56():93-120. PubMed ID: 18086410
    [No Abstract]   [Full Text] [Related]  

  • 6. Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
    Rivero-Buceta E; Doyagüez EG; Colomer I; Quesada E; Mathys L; Noppen S; Liekens S; Camarasa MJ; Pérez-Pérez MJ; Balzarini J; San-Félix A
    Eur J Med Chem; 2015 Dec; 106():34-43. PubMed ID: 26513643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbicide drug candidates to prevent HIV infection.
    Balzarini J; Van Damme L
    Lancet; 2007 Mar; 369(9563):787-797. PubMed ID: 17336656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors.
    Farr C; Nomellini JF; Ailon E; Shanina I; Sangsari S; Cavacini LA; Smit J; Horwitz MS
    PLoS One; 2013; 8(6):e65965. PubMed ID: 23840383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Emerging Drug Targets for Human Immunodeficiency Virus.
    Waheed AA; Tachedjian G
    Curr Top Med Chem; 2016; 16(10):1072-3. PubMed ID: 26381413
    [No Abstract]   [Full Text] [Related]  

  • 11. [The HIV replication cycle. Established therapeutic targets and potential targets].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():3-10. PubMed ID: 19572419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
    Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
    J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.
    Harman S; Herrera C; Armanasco N; Nuttall J; Shattock RJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2347-56. PubMed ID: 22330930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current State of Microbicide Development.
    Traore YL; Chen Y; Ho EA
    Clin Pharmacol Ther; 2018 Dec; 104(6):1074-1081. PubMed ID: 30107032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.
    Buckheit KW; Furlan-Freguia C; Ham AS; Buckheit RW
    Curr Top Med Chem; 2016; 16(10):1118-34. PubMed ID: 26324047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped.
    Doms RW
    Top HIV Med; 2004; 12(4):100-3. PubMed ID: 15516706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Past, present, and future of entry inhibitors as HIV microbicides.
    Gibson RM; Arts EJ
    Curr HIV Res; 2012 Jan; 10(1):19-26. PubMed ID: 22264042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting strategies for Human immunodeficiency virus: a combinatorial approach.
    Saxena SK; Gupta A; Bhagyashree K; Saxena R; Arora N; Banerjee AK; Tripathi AK; Chandrasekar MJ; Gandhi N; Nair MP
    Mini Rev Med Chem; 2012 Mar; 12(3):236-54. PubMed ID: 22356194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
    Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
    Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The world of HIV and disease, and some new approaches to block it.
    Gallo R
    Bull Mem Acad R Med Belg; 1998; 153(7-9):339-42. PubMed ID: 10100397
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.